<DOC>
	<DOC>NCT01185301</DOC>
	<brief_summary>The purpose of this study is to determine the effects of different doses of methotrexate (MTX) when taken with adalimumab in subjects with early rheumatoid arthritis (RA).</brief_summary>
	<brief_title>Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male and female subjects at least 18 years of age Subject has a diagnosis of Rheumatoid Arthritis (RA) as defined by either the 1987revised American College of Rheumatology (ACR) classification criteria or the new ACR/ European League Against Rheumatism (EULAR) diagnostic criteria for RA 2010 and has a disease duration of less than 1 year from diagnosis by a licensed health care provider Subject must meet the following criteria: 1. Disease Activity Score of Creactive Protein (DAS28[CRP]) ≥ 3.2 (at the Baseline visit only) 2. At least 6 swollen joints out of 66 assessed (at the Screening and Baseline visits) 3. At least 8 tender joints out of 68 assessed (at the Screening and Baseline visits) 4. Creactive protein (CRP) ≥ 1.5 mg/dL (at the Screening visit only), or erythrocyte sedimentation rate (ESR) ≥ 28 mm/1h (at the Screening and Baseline visits) 5. Fulfill at least one of the following three criteria: Rheumatoid Factor (RF) positive, have at least 1 bony erosion, anticyclic citrullinated peptide (antiCCP) antibody positive Subject is judged to be in good health as determined by the Principal Investigator based upon the results of medical history, laboratory profile, physical examination, chest xray (CXR), and a 12lead electrocardiogram (ECG) performed during Screening Subject has previous exposure to any systemic biologic therapy including adalimumab Subject has been previously treated with greater than 1 disease modifying antirheumatic drugs (DMARDs) or with methotrexate (MTX) Subject has undergone joint surgery within the preceding two months (at joints to be assessed within the study) Subject has chronic arthritis diagnosed before age 17 years History of invasive infection (e.g., listeriosis and histoplasmosis), chronic or active Hepatitis C infection, human immunodeficiency virus (HIV) infection, immunodeficiency syndrome, chronic recurring infections or active tuberculosis (TB) Hepatitis B virus: hepatitis B surface antigen (HBs Ag) positive (+) or detected sensitivity on the hepatitis B virus DNA (HBV DNA) polymerase chain reaction (PCR) qualitative test Infection(s) requiring treatment with intravenous (IV) antiinfectives within 30 days prior to the Baseline Visit or oral antiinfectives within 14 days prior to the Baseline visit Female subject who is pregnant or breastfeeding or considering becoming pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Arthritis</keyword>
	<keyword>Erosion</keyword>
	<keyword>Humira</keyword>
	<keyword>Adalimumab</keyword>
	<keyword>Injection</keyword>
	<keyword>Rheumatoid</keyword>
	<keyword>Methotrexate</keyword>
</DOC>